Stratamark is the only topical product for the prevention and treatment of Striae with proven clinical evidence1

The first Stratamark publication1 demonstrating the efficacy evidence for both prevention and treatment of stretch marks.

A volunteer sample of 303 women, presenting to 61 different Obstetricians in Czech Republic (Europe) for obstetric care participated in the study.

Subjects were divided into two arms:

Prevention: 148 pregnant women with no existing Striae Distensae.

Treatment: 155 women with existing Striae Distensae (both Striae Alba and Striae Rubra) prior to their study participation.

Within the treatment arm some women started their treatment during their current pregnancy as they had pre-existing Srtriae Distensae and some patients started their treatment as late as post-delivery. Many of the women recruited into the treatment arm did not have existing Striae Distensae, had declined participation in the prevention group, and as they developed Striae Distensae during their pregnancy and/or post-delivery, requested to become part of the treatment arm.

All women were instructed not to use other creams or lotions during the study period. All women were asked to apply the gel once per day, and it was explained that the best results were expected if the product was in contact with the skin 24 hours a day 7 days a week (24/7).

Those that used the gel less than 6 days per week were excluded from the study.

Study Results – Prevention Arm


*Data from: Osman H et al. BJOG 2008;115:1138–1142
The reported prevalence of Striae ranges between 50–90 %, with most control groups showing between 60 % and 70 % developed during pregnancy, depending on the population studied.2,3


Study Results – Treatment Arm




1. Malkova S. The effect of innovative gel in the prevention and treatment of Striae Distensae (Stratamark gel). New EU Magazine of Medicine, July 2014, 1–4/2014.
2. Osman H et al. BJOG 2008; 115:1138–1142
3. Elsaie ML et al. Dermatologic Surgery 2009; 35:563–573